Search - tctmd.com

Displaying 381 - 400 of 3312

Sort: Relevancy | Date

News Daily News

Mortality Risk Varies Among Patients With Very High LDL Levels

Michael O'Riordan

November 17, 2023

News Conference News AHA 2023

Novel AI-Guided CV Risk Prediction Takes Aim at Coronary Inflammation

L.A. McKeown

November 17, 2023

News Conference News AHA 2023

Seeing Sticker Price for HFrEF Meds Opens Door to Discussions

Caitlin E. Cox

November 14, 2023

News Conference News AHA 2023

Large, Sustained Reductions in Lp(a) With Lepodisiran in Phase I Study

Michael O'Riordan

November 13, 2023

News Conference News AHA 2023

New PCSK9 Inhibitor Halves LDL: Will Protracted Dosing Make a Difference?

Shelley Wood

November 13, 2023

AZALEA-TIMI 71: Abelacimab Slashes Bleeds vs Rivaroxaban in AF, but Stroke Impact Unclear

News Conference News AHA 2023

NOW PUBLISHED - AZALEA-TIMI 71: Bleeds Plunge With Abelacimab vs Rivaroxaban in AF, but Stroke Impact Unclear

L.A. McKeown

November 12, 2023

News Conference News AHA 2023

Gene Editing Shuts Off PCSK9 to Lower LDL in HeFH

Caitlin E. Cox

November 12, 2023

News Conference News AHA 2023

Full SELECT Results Affirm CV Risk Reduction With Semaglutide in Nondiabetics

Todd Neale

November 11, 2023

News Conference News AHA 2023

DAPA-MI: Cardiometabolic Endpoints ‘Win’ With Dapagliflozin After Acute MI

Shelley Wood

November 11, 2023

News Daily News

FDA Grants Tirzepatide a New Indication for Obesity Management

L.A. McKeown

November 08, 2023

News Conference News AHA 2023

Inflammation More Powerful Than LDL as CV Risk Predictor in Statin-Free Patients

Caitlin E. Cox

November 07, 2023

News Opinion Editor's Corner AHA 2023

What’s Going to Be Hot at AHA 2023

Shelley Wood

November 07, 2023

News Daily News

Very High LDL Cholesterol Declines in US Adults, but Progress Is Slow

Michael O'Riordan

November 02, 2023

News Conference News TCT 2023

Sirolimus- and Paclitaxel-Coated Balloons Well-Matched for In-Stent Restenosis

Todd Neale

November 02, 2023

News Conference News VIVA 2023

PROMISE II: Deep-Vein Arterialization Durable for Amputation-Free Survival in CLTI

L.A. McKeown

November 01, 2023

News Opinion CV Team Dispatch

November 2023 News Roundup

L.A. McKeown

November 01, 2023

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for October 2023

Shelley Wood

November 01, 2023

News Conference News TCT 2023

TRILUMINATE Deep Dive Clarifies ‘Meaningful’ QoL Gains With Tricuspid TEER

Yael L. Maxwell

October 26, 2023

News Conference News TCT 2023

In ACS, Ticagrelor Only After < 1 Month DAPT Beats Continuing Aspirin: T-PASS

Yael L. Maxwell

October 25, 2023

News Conference News TCT 2023

LIFE-BTK: Bioresorbable Scaffold Holds Promise for Infrapopliteal CLTI

L.A. McKeown

October 25, 2023

Advertisement

Mortality Risk Varies Among Patients With Very High LDL Levels

Novel AI-Guided CV Risk Prediction Takes Aim at Coronary Inflammation

Seeing Sticker Price for HFrEF Meds Opens Door to Discussions

Large, Sustained Reductions in Lp(a) With Lepodisiran in Phase I Study

New PCSK9 Inhibitor Halves LDL: Will Protracted Dosing Make a Difference?

NOW PUBLISHED - AZALEA-TIMI 71: Bleeds Plunge With Abelacimab vs Rivaroxaban in AF, but Stroke Impact Unclear

Gene Editing Shuts Off PCSK9 to Lower LDL in HeFH

Full SELECT Results Affirm CV Risk Reduction With Semaglutide in Nondiabetics

DAPA-MI: Cardiometabolic Endpoints ‘Win’ With Dapagliflozin After Acute MI

FDA Grants Tirzepatide a New Indication for Obesity Management

Inflammation More Powerful Than LDL as CV Risk Predictor in Statin-Free Patients

What’s Going to Be Hot at AHA 2023

Very High LDL Cholesterol Declines in US Adults, but Progress Is Slow

Sirolimus- and Paclitaxel-Coated Balloons Well-Matched for In-Stent Restenosis

PROMISE II: Deep-Vein Arterialization Durable for Amputation-Free Survival in CLTI

November 2023 News Roundup

TCTMD’s Top 10 Most Popular Stories for October 2023

TRILUMINATE Deep Dive Clarifies ‘Meaningful’ QoL Gains With Tricuspid TEER

In ACS, Ticagrelor Only After < 1 Month DAPT Beats Continuing Aspirin: T-PASS

LIFE-BTK: Bioresorbable Scaffold Holds Promise for Infrapopliteal CLTI

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content